Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03075605
Other study ID # PRO08010374
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 20, 2008
Est. completion date December 31, 2019

Study information

Verified date March 2021
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective case control study that compares the initial immune response with severity and outcome in patients with acute pancreatitis.


Description:

This is a prospective case control study that compares the initial immune response with severity and outcome in patients with acute pancreatitis. Therefore, the investigators aim to determine whether etiology of acute pancreatitis, segregates with candidate genetic polymorphisms and their m-RNA expression, as well as whether functional polymorphisms in inflammation regulating genes predict a more severe outcome in acute pancreatits. The investigators anticipate that based on our results that we will provide a more accurate predictor of the clinical course of acute pancreatits and help direct more aggressive or cytokine specific treatment of patients at greater risk of a more severe form of the disease.


Recruitment information / eligibility

Status Completed
Enrollment 723
Est. completion date December 31, 2019
Est. primary completion date July 5, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Year and older
Eligibility Inclusion Criteria: - Inclusion criteria for Subjects (all three) Males and females of 16 years of age and older. Body weight at least 40kg Diagnosis of acute pancreatitis by both: Abdominal pain or abdominal localizing signs AND Elevated amylase levels by at-least three times the upper limit of normal and/or elevated lipase levels by at-least three times the upper limit of normal (25, 26). Acute pancreatitis must be defined by 2 of the 3 following criteria: - Serum amylase or lipase elevated greater than 3X upper limit of normal - epigastric acute pancreatitis pain - abdominal imaging studies demonstrating pancreatic edema, peripancreatic fat stranding or complications or acute pancreatitis Willingness to participate in the study and sign the informed consent. (Children and subjects who are cognitively impaired for temporary reasons as mentioned in the section 4.7 of this protocol will require a representative to sign the informed consent). Inclusion criteria for Controls (all three) Males and females of 18 years of age and older. a. Unrelated family member or a friend of the subject or a patient having blood drawn in general medicine outpatient clinic, without a history of pancreatitis, OR Willingness to participate in the study and sign the informed consent. Additional Inclusion Criteria for subjects with a previous attack of acute pancreatitis: age criteria as defined above. - Previous severe attack of severe acute pancreatitis requiring a ICU stay of at least 48 hours or evidence of pancreatic necrosis on computerized tomography. Willingness to participate and sign informed consent Exclusion Criteria: - Exclusion Criteria for Subjects: Persons unwilling to sign the informed consent Disorientation secondary to irreversible organic brain damage. Mean corpuscular volume (MCV) of less than 77 in all children of 18 years or younger. Blood transfusion within one week of enrollment Chronic Pancreatitis History of pancreatic cancer History of cancer requiring chemotherapy or radiation within the past 1 year History of organ transplant Subject is a prisoner Pancreatitis due to multiple trauma or surgical complications Exclusion criteria for Controls: Persons unwilling to sign the informed consent

Study Design


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Pittsburgh

Outcome

Type Measure Description Time frame Safety issue
Primary Severe Acute Pancreatitis (defined as persistent organ failure) To compare the initial immune response in patients who developed mild vs. severe disease. To determine whether functional polymorphisms in inflammation regulating genes predicts a more severe outcome in acute pancreatitis. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT03609944 - SpHincterotomy for Acute Recurrent Pancreatitis N/A
Not yet recruiting NCT04652271 - International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
Completed NCT01441492 - Pancreas Resection With and Without Drains N/A
Recruiting NCT02196935 - Los Angeles Prospective GI Biliary and EUS Series
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01545167 - The North American Pancreatitis Study N/A
Completed NCT04168801 - Early Oral Refeeding in Mild Acute Pancreatitis N/A
Recruiting NCT03334708 - A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Completed NCT01824186 - Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy N/A
Terminated NCT00428025 - Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients Phase 4
Completed NCT00639314 - Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy N/A
Recruiting NCT00160836 - Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter Phase 1
Completed NCT00121901 - Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis? Phase 3
Completed NCT00999232 - Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube Phase 4
Terminated NCT00419549 - Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP) Phase 2/Phase 3
Active, not recruiting NCT05095831 - EUS Shear Wave for Solid Pancreatic Lesions.
Completed NCT03601325 - Acute Pancreatitis: Study of Possible Etiologies and Risk Factors Affecting Outcome
Withdrawn NCT02465138 - A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis Phase 4
Not yet recruiting NCT06133023 - WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts N/A
Recruiting NCT02971475 - ESWL Versus ESWL and Endoscopic Treatment N/A